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Vancomycin-
resistant 
Enterococci, 
Mexico City
To the Editor: Vancomycin-resis-
tant Enterococcus (VRE) has become 
an important nosocomial pathogen 
because of its rapid spread, limited 
therapy options, mortality, and the 
possibility of transfer of vancomycin 
resistance to other pathogens such as 
Staphylococcus aureus. Vancomycin-
resistant  E. faecium (VREF) and E. 
faecalis were ﬁ  rst described in 1988 
(1,2).They have become major noso-
comial pathogens, but their preva-
lence in Latin America has remained 
<2% (3). In Mexico, VRE has rarely 
been reported (4,5). In a recent study 
in Mexico City, 100% (n = 60) of the 
isolates of E. faecium and E. faecalis 
were susceptible to vancomycin (6).
From May 2004 to April 2005, the 
rate of vancomycin resistance among 
all Enterococcus isolates was 0.27%. 
However, in May 2005 the ﬁ  rst fully 
VREF was isolated at our hospital, 
and the rate of vancomycin resistance 
was 6.23% (a 23-fold increase) during 
the following 12-month period. 
We performed a retrospective 
study to describe the isolates and the 
characteristics of patients with VREF. 
All VREF isolates from May 2005 
through April 2006 were included. We 
collected demographic and clinical 
data. For the ﬁ  nal identiﬁ  cation of the 
isolates, the VITEK system (bioMéri-
eux, Lyon, France) with VITEK GPI 
cards (bioMérieux, Inc., Durham NC, 
USA) were used. Antimicrobial drug 
susceptibility was tested by using the 
VITEK GPS-111 card and conﬁ  rmed 
by MIC determination that used broth 
microdilution. Resistance to vancomy-
cin and teicoplanin was conﬁ  rmed by 
E-test (AB Biodisk, Solna, Sweden). 
An isolate was considered vancomy-
cin resistant when the MIC was >32 
μg/mL and was considered to have 
high-level resistance when the MIC 
was ≥256 μg/mL. A PCR for detec-
tion of the vanA or vanB genotype was 
used (7). Isolates were characterized 
by pulsed-ﬁ   eld gel electrophoresis 
(PFGE) (8,9); a dendrogram was con-
structed with the GelCompare II 4.0 
software (Applied Maths, Kortrijk, 
Belgium), and the similarity was com-
pared with the Dice coefﬁ  cient.
In the study period, VREF was 
isolated from 27 patients. The me-
dian age was 40 years (range 22–84 
years). VREF was isolated from the 
abdomen in 14 patients (51.9%); 
11 isolates were from an abscess, 2 
from infected surgical sites, and 1 
from ascites. An additional 8 isolates 
were from the urinary tract (29.6%), 
2 from the bloodstream (7.4%), 2 
from soft-tissue (7.4%), and 1 (3.7%) 
from bone. Residence in the general 
medical wards during the isolation of 
VREF was most common, 17 (63%) 
cases, followed by 6 (22.2%) in the 
intensive care unit. The remaining 
4 (14.8%) were distributed in other 
areas. Median time of hospitaliza-
tion before the isolation was 21 days 
(range 1–84 days). Twenty-ﬁ  ve  pa-
tients (92.6%) had a central line, 12 
(44.4%) had mechanical ventilation, 
and 20 (74.1%) previous surgery. Of 
the last group, 17 (85%) of 20 had 
abdominal surgery. Twenty-four pa-
tients (88.8%) received an antimi-
crobial drug before the isolation of 
VREF: third- or fourth-generation 
cephalosporins (89%), metronidazole 
(70.4%),  aminoglycosides (70.4%),   
vancomycin (66.7%),  carbapenems 
(66.7%), amoxicillin or ampicillin 
(48.1%), antifungal agents (48.1%); 
and <20% received quinolones, trim-
ethoprim-sulfamethoxazole, colistin, 
macrolides, and antimycobacterial or 
antiviral agents. The median time of 
antimicrobial drug use was 11 days 
(range 1–84 days). During hospital-
ization, 7 patients died (crude death 
rate, 25.9%), 5 of them from sepsis 
with at least another microorganism 
isolated; the remaining 2 died of gas-
trointestinal hemorrhage.
All isolates of E. faecium had a 
vancomycin MIC >256 μg/mL and a 
vanA phenotype (teicoplanin resis-
tance); 26 (96.3%) had vanA geno-
type. Only 1 isolate of E. faecium was 
classiﬁ   ed as non–vanA, non vanB, 
even though it demonstrated high-lev-
el resistance to vancomycin and teico-
planin. Resistance to other antimicro-
bial agents was as follows: ampicillin 
and ciproﬂ   oxacin, 100%; high-level 
gentamicin, 48.2%; quinupristin/dal-
fopristin, 7.4%; and linezolid, 0%.
PFGE analysis showed several 
genotypes of E. faecium; however, 18 
of 26 of the isolates had <3 band dif-
ferences from the predominant strain 
classiﬁ  ed as type A. One isolate of E. 
faecium could not be typed (Figure).
As in most tertiary-care centers, 
our PFGE data suggest that a heterog-
enous population of VREF exists, but 
a particular clone established itself as 
the dominant strain. Although infec-
tion control measures are well estab-
lished in our hospital, in disseminated 
outbreaks caused by several different 
clones, infection control measures 
and control of vancomycin use have 
shown only limited efﬁ  cacy. This sug-
gests selection pressure by antimicro-
bial drugs other than vancomycin (10). 
Early detection of VREF is of extreme 
importance because of the possibility 
that the vanA gene may be transferred 
to a variety of gram-positive microor-
ganisms, including S. aureus. 
The rate of isolation of VREF at 
our hospital increased considerably 
during the last year. Even though the 
number of patients is small, we consid-
er this ﬁ  nding to be of utmost impor-
tance, since VREF seems to be emerg-
ing in Mexico. To our knowledge, this 
is the ﬁ  rst well-documented outbreak 
of high-level resistance to vancomy-
cin in enterococci in Mexico. Further 
research is needed to determine if the 
problem is limited to our hospital or if 
it is a nationwide trend.LETTERS
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Disseminated 
Bacillus Calmette-
Guérin Infection and 
Immunodeﬁ  ciency
To the Editor: Disseminated ba-
cillus Calmette-Guérin (BCG) infec-
tion has been noted in patients with 
primary immunodeﬁ  ciency. Incidence 
rates have ranged from 0.06 to 1.56 
cases per million vaccinated, and mor-
tality rates have remained at ≈60% 
(1–7).  Of 946 patients with primary 
immunodeﬁ  ciency, including 29 with 
severe combined immunodeﬁ  ciencies, 
diagnosed from 1980 through 2006 at 
the Children’s Memorial Health Insti-
tute in Warsaw, adverse events after 
BCG vaccination were observed in 16 
(8,9). All 16 were children who had 
been vaccinated at birth with BCG, 
Brazilian strain (Biomed, Lublin,       
Poland). 
Four patients with severe com-
bined immunodeﬁ  ciency showed ad-
verse reactions to BCG. Patient M.K. 
had mild inﬂ  ammation at the site of 
the BCG injection and was success-
fully treated with rifampin. The patient 
subsequently received a bone marrow 
transplant, and 2 months later poor ap-
petite, failure to thrive, and subfebrile 
condition were noted. Disseminated 
skin changes (with pus formation in 
the subcutaneous layer), osteomyeli-
tis, and multiple lesions in the liver 
were found. A skin biopsy showed 
tuberculoma formations, which were 
PCR-positive for Mycobacterium tu-
berculosis complex (Ampliﬁ  ed Myco-
Figure. Pulsed-ﬁ  eld gel electrophoresis (PFGE) banding patterns of chromosomal DNA 
of 26 isolates of vancomycin-resistant enterococci. There is a clear predominant type, 
classiﬁ  ed as type A (>80% similarity), composed of 18 isolates of Enterococcus faecium. 
There are at least 3 subtypes that display a 100% similarity.